TABLE 1.
Demographic and treatment characteristics of 28 neonates with invasive candidiasis and pharmacokinetic sampling following ABLC therapy
| Parameter and unitb | Valuea
|
||
|---|---|---|---|
| ABLC at 2.5 mg/kg (n = 15) | ABLC at 5.0 mg/kg (n = 13) | All patients (n = 28) | |
| Gender (no. of males/no. of females) | 11/4 | 7/6 | 18/10 |
| Gestational age (wk) | 27 (24-40) | 28 (24-41) | 27 (24-41) |
| Birth wt (g) | 820 (470-4,600) | 980 (460-4,400) | 910 (460-4,600) |
| Age at BL (days) | 23 (10-89) | 31 (8-73) | 27 (8-89) |
| Wt at BL (g) | 970 (480-4,900) | 1,300 (840-4,400) | 1,060 (480-4,900) |
| No. of patients with prior DAMB (yes/no) | 10/5 | 5/8 | 15/13 |
| No. of days on therapy with ABLC | 21 (4-47) | 20 (5-35) | 21 (4-47) |
a
Single numbers are medians, and numbers in parentheses are ranges.
b
BL, baseline (start of therapy with ABLC).